MedTrace Logo

Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects

NCT02207595 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-03-05

No results posted yet for this study

Summary

The primary objective of this study is to investigate the safety and tolerability of UCB5857.

Conditions

  • Healthy Volunteers

Interventions

DRUG

UCB5857

* Active Substance: UCB5857 * Pharmaceutical Form: Capsule * Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg * Route of Administration: Oral Use

OTHER

Placebo

* Active Substance: Placebo * Pharmaceutical Form: Capsule * Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg * Route of Administration: Oral Use

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • UCB Celltech

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02207595 on ClinicalTrials.gov